These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 17320833)
21. The clinical use of P300 event related potentials for the evaluation of cholinesterase inhibitors treatment in demented patients. Werber EA; Gandelman-Marton R; Klein C; Rabey JM J Neural Transm (Vienna); 2003 Jun; 110(6):659-69. PubMed ID: 12768361 [TBL] [Abstract][Full Text] [Related]
23. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Butterfield DA; Reed TT; Perluigi M; De Marco C; Coccia R; Keller JN; Markesbery WR; Sultana R Brain Res; 2007 May; 1148():243-8. PubMed ID: 17395167 [TBL] [Abstract][Full Text] [Related]
28. The difference of mild cognitive impairment in Parkinson's disease from amnestic mild cognitive impairment: Deeper power decrement and no phase-locking in visual event-related responses. Yener GG; Fide E; Özbek Y; Emek-Savaş DD; Aktürk T; Çakmur R; Güntekin B Int J Psychophysiol; 2019 May; 139():48-58. PubMed ID: 30851280 [TBL] [Abstract][Full Text] [Related]
29. Key lessons learned from short-term treatment trials of cholinesterase inhibitors for amnestic MCI. Salloway S; Correia S; Richardson S Int Psychogeriatr; 2008 Feb; 20(1):40-6. PubMed ID: 17597552 [TBL] [Abstract][Full Text] [Related]
30. Inefficient response inhibition in individuals with mild cognitive impairment. Wylie SA; Ridderinkhof KR; Eckerle MK; Manning CA Neuropsychologia; 2007 Apr; 45(7):1408-19. PubMed ID: 17178419 [TBL] [Abstract][Full Text] [Related]
31. Short latency afferent inhibition differs among the subtypes of mild cognitive impairment. Nardone R; Bergmann J; Christova M; Caleri F; Tezzon F; Ladurner G; Trinka E; Golaszewski S J Neural Transm (Vienna); 2012 Apr; 119(4):463-71. PubMed ID: 22016008 [TBL] [Abstract][Full Text] [Related]
32. Evoked potential findings in Behçet's disease. Brain-stem auditory, visual, and somatosensory evoked potentials in 44 patients. Stigsby B; Bohlega S; al-Kawi MZ; al-Dalaan A; el-Ramahi K Electroencephalogr Clin Neurophysiol; 1994 Jul; 92(4):273-81. PubMed ID: 7517849 [TBL] [Abstract][Full Text] [Related]
33. Shifting efficacy, distribution of attention and controlled processing in two subtypes of mild cognitive impairment: response time performance and intraindividual variability on a visual search task. McLaughlin PM; Borrie MJ; Murtha SJ Neurocase; 2010 Oct; 16(5):408-17. PubMed ID: 20401803 [TBL] [Abstract][Full Text] [Related]
36. [Evoked potentials and age: different aging by sex?]. Lille F; Hassine L; Margules S Neurophysiol Clin; 1991 Dec; 21(5-6):459-72. PubMed ID: 1808504 [TBL] [Abstract][Full Text] [Related]
37. Study protocol for a randomised, double-blind, placebo-controlled 12-week pilot phase II trial of Sailuotong (SLT) for cognitive function in older adults with mild cognitive impairment. Steiner GZ; Bensoussan A; Liu J; Hohenberg MI; Chang DH Trials; 2018 Sep; 19(1):522. PubMed ID: 30253809 [TBL] [Abstract][Full Text] [Related]
38. A clinical memory battery for screening for amnestic mild cognitive impairment in an elderly chinese population. Zhao S; Guo C; Wang M; Chen W; Wu Y; Tang W; Zhao Y J Clin Neurosci; 2011 Jun; 18(6):774-9. PubMed ID: 21435882 [TBL] [Abstract][Full Text] [Related]